Meeting
2012 ASCO Annual Meeting
Hearing evaluation of head and neck cancer patients (HNCP): Comparison of adverse event (AE) criteria.
Authors
A. Dimitrios Colevas
Stanford University School of Medicine, Stanford, CA
A. Dimitrios Colevas , Ruth R Lira , Electra A Colevas , Philip W. Lavori , Kay W Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5525)
DOI
10.1200/jco.2012.30.15_suppl.5525
Abstract #
5525
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Quality Care Symposium
Barriers and facilitators to the implementation of routine ototoxicity screening for head and neck cancer patients.
First Author: Priya Bapat
Poster
2018 ASCO Annual Meeting
Incidence of ototoxicity in head and neck cancer (HNSCC) patients (pts) receiving concomitant chemo-radiation (CRT) with weekly or triweekly cisplatin (Cis).
First Author: Jishu Das
Poster
2022 ASCO Quality Care Symposium
Impact of statin type and intensity on cisplatin-related hearing loss.
First Author: Emilee McCullough
Poster
2022 ASCO Annual Meeting
The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.
First Author: Sara Kuruvilla